Navigation Links
BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
Date:12/8/2011

JUPITER, Fla., Dec. 8, 2011 /PRNewswire/ -- BioRestorative Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it has entered into a Material Manufacturing Agreement with the University of Utah.  Pursuant to the agreement, the University of Utah has been retained to manufacture certain materials derived from stem cells.

The agreement marks the next step in the development of a strategic collaboration between BRT and the University of Utah, an institution recognized as a leader in translational stem cell-based therapies. 

Dr. Amit Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah, said, "We are pleased that we are expanding our relationship with BRT and are excited to be working with them on their scientific and clinical programs. The University's stem cell laboratories have the unique skills and capacities to assist BRT in producing their stem cell derived materials."

Mark Weinreb, Chairman and CEO of BRT, said, "BRT is fortunate to be partnering with the University of Utah and Dr. Patel's team of stem cell experts. This represents the commencement of laboratory operations and we look forward to additional research and clinical collaborations."

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a medical center of excellence using cell and tissue protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. In June 2011, the Company launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem Program.  The ThermoStem Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for clinical procedures and outcomes for future personal medical applications.  The Company also plans to offer and sell facial creams and products under the Stem Pearls™ brand.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Mark Weinreb
CEO                                      
Tel: (561) 904-6070
Fax: (561) 429-5684


'/>"/>
SOURCE BioRestorative Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioRestorative Therapies, Inc. Begins Trading Under New Name and Symbol ("BRTX")
2. BioRestorative Therapies, Inc. Announces Upgrade to OTCQB Market
3. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
4. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
5. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
6. Steve Jobs Death Highlights Critical Need for New Therapies for Pancreatic Cancer
7. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
8. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
9. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
10. Americans Travel to Mexico for Stem Cell Stimulation Therapies and E+ Peptide Cancer Vaccine -- Treatments Not Yet Offered in U.S.
11. Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX ... global Phase 2b induction study in ulcerative colitis ... integrin. The aim of this randomized, double-blind, placebo-controlled, ... and efficacy of PTG-100 in approximately 240 adult ... disease. "We are very pleased ...
(Date:1/16/2017)... NY (PRWEB) , ... January 16, 2017 , ... ... New Jersey laws precedential publication its decision on the appeal filed by India-based ... lawsuit of breach of contract against DPCL and one of its Dishman Group’s ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Tibbetts Award from the U.S. Small Business Administration. The Tibbetts Award ... economic or social impact […] and are considered the best of the best ...
(Date:1/14/2017)... ... 14, 2017 , ... Seattle-based Phase Genomics has announced the ... researchers around the globe. Long considered a “holy grail” in biological research, ... of scientific questions. The announcement was made today at the Plant & ...
Breaking Biology Technology:
(Date:12/15/2016)... -- ... Research and Markets has announced the addition of the "Global Military ... report forecasts the global military biometrics market to grow at a CAGR ... been prepared based on an in-depth market analysis with inputs from industry ... the coming years. The report also includes a discussion of the key ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
Breaking Biology News(10 mins):